Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$210.28
+0.4%
$192.84
$163.81
$218.66
$372.04B0.55.18 million shs5.52 million shs
Morgan Stanley stock logo
MS
Morgan Stanley
$147.93
+2.7%
$141.29
$94.09
$149.08
$236.15B1.324.76 million shs6.76 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
0.00%+1.76%+10.55%+14.59%+6.45%
Morgan Stanley stock logo
MS
Morgan Stanley
0.00%+2.34%+3.45%+17.27%+45.19%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
4.7611 of 5 stars
2.54.03.33.93.92.51.3
Morgan Stanley stock logo
MS
Morgan Stanley
4.3815 of 5 stars
1.24.04.22.42.32.52.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.96
Moderate Buy$214.952.22% Upside
Morgan Stanley stock logo
MS
Morgan Stanley
2.47
Hold$138.25-6.55% Downside

Current Analyst Ratings Breakdown

Latest ABBV and MS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/12/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$231.00
8/11/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/7/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Daiwa America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
8/7/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Daiwa Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Outperform$214.00
8/1/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$250.00 ➝ $255.00
8/1/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$216.00 ➝ $227.00
8/1/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$227.00 ➝ $236.00
7/9/2025
Morgan Stanley stock logo
MS
Morgan Stanley
Keefe, Bruyette & Woods
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$127.00 ➝ $160.00
7/8/2025
Morgan Stanley stock logo
MS
Morgan Stanley
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$120.00 ➝ $145.00
6/18/2025
Morgan Stanley stock logo
MS
Morgan Stanley
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$125.00 ➝ $130.00
6/11/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold$205.00
(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$56.33B6.59$14.91 per share14.10$1.90 per share110.68
Morgan Stanley stock logo
MS
Morgan Stanley
$107.29B2.20$11.51 per share12.85$59.39 per share2.49
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.28B$2.10100.1415.041.356.45%699.66%13.64%10/29/2025 (Estimated)
Morgan Stanley stock logo
MS
Morgan Stanley
$13.39B$8.8316.7515.691.8513.06%15.20%1.15%10/15/2025 (Estimated)

Latest ABBV and MS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/31/2025Q2 2025
AbbVie Inc. stock logo
ABBV
AbbVie
$3.24$2.97-$0.27$0.52$14.93 billion$15.42 billion
7/16/2025Q2 2025
Morgan Stanley stock logo
MS
Morgan Stanley
$1.98$2.13+$0.15$2.13$16.15 billion$16.79 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.563.12%N/A312.38%53 Years
Morgan Stanley stock logo
MS
Morgan Stanley
$4.002.70%N/A45.30%12 Years

Latest ABBV and MS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/20/2025
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.643.54%7/15/20257/15/20258/15/2025
7/18/2025
Morgan Stanley stock logo
MS
Morgan Stanley
quarterly$1.002.6%7/31/20257/31/20258/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
44.14
0.74
0.61
Morgan Stanley stock logo
MS
Morgan Stanley
3.30
0.78
0.78

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Morgan Stanley stock logo
MS
Morgan Stanley
84.19%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.08%
Morgan Stanley stock logo
MS
Morgan Stanley
0.19%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
55,0001.77 billion1.77 billionOptionable
Morgan Stanley stock logo
MS
Morgan Stanley
80,0001.60 billion1.59 billionOptionable

Recent News About These Companies

Allstate Corp Decreases Stock Position in Morgan Stanley $MS
Morgan Stanley on AI: Big Spending, Big Value Creation
Morgan Stanley (MS) Stock Price Today - WSJ
Insider Sale: CALO & Corp. Secretary of $APP Sells 509 Shares
Insider Sale: See Remarks of $PLTR Sells 74 Shares
Insider Sale: SVP & CCO of $AMGN Sells 1,267 Shares
Insider Sale: EVP of $IRTC Sells 653 Shares
Why Morgan Stanley (MS) Stock Is Trading Up Today
Insider Sale: See Remarks of $HLT Sells 11,905 Shares
Insider Sale: Executive Vice President of $COST Sells 600 Shares
$PYPL stock is up 3% today. Here's what we see in our data.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AbbVie stock logo

AbbVie NYSE:ABBV

$210.28 +0.78 (+0.37%)
Closing price 08/22/2025 03:59 PM Eastern
Extended Trading
$210.12 -0.17 (-0.08%)
As of 08/22/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Morgan Stanley stock logo

Morgan Stanley NYSE:MS

$147.93 +3.89 (+2.70%)
Closing price 08/22/2025 03:59 PM Eastern
Extended Trading
$148.22 +0.28 (+0.19%)
As of 08/22/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Morgan Stanley, a financial holding company, provides various financial products and services to corporations, governments, financial institutions, and individuals in the Americas, Europe, the Middle East, Africa, and Asia. It operates through Institutional Securities, Wealth Management, and Investment Management segments. The Institutional Securities segment offers capital raising and financial advisory services, including services related to the underwriting of debt, equity, and other securities, as well as advice on mergers and acquisitions, restructurings, real estate, and project finance. This segment also provides equity and fixed income products comprising sales, financing, prime brokerage, and market-making services; foreign exchange and commodities; corporate and commercial real estate loans, commercial mortgage and secured lending facilities, and financing for sales and trading customers, and asset-backed and mortgage lending; and wealth management services, investment, and research services. The Wealth Management segment offers financial advisor-led brokerage, custody, administrative, and investment advisory services; self-directed brokerage services; financial and wealth planning services; workplace services, including stock plan administration; annuity and insurance products; securities-based lending, residential real estate loans, and other lending products; banking; and retirement plan services to individual investors and small to medium-sized businesses and institutions. The Investment Management segment provides equity, fixed income, alternatives and solutions, and liquidity and overlay services to benefit/defined contribution plans, foundations, endowments, government entities, sovereign wealth funds, insurance companies, third-party fund sponsors, corporations, and individuals through institutional and intermediary channels. The company was founded in 1924 and is headquartered in New York, New York.